Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Среда, 31 декабря 2008 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Новая вакансия


Включен в программу ОНЛС

  1. Agostini L, Down PF, Murison J, Wrong OM. Faecal ammonia and pH during lactulose administration in man: comparison with other cathartics. Gut 1972; 13:859-866.
  2. Altucci P, Algia I, Leonessa V, et al. Sulla durata della escrezione di Salmonelle da „portatori" e sulla sua influenzabilita da parte di vari trattamenti [On the duration of salmonella excretion in the carrier subjects]. G Mal Infett Paras-sit 1981; 33:530-531.
  3. AMA-American Medical Association: Drug evaluations annual 1992.
  4. Anonymus. Drug resistance in Salmonellas. Lancet 1982; 1 (June 19): 1391-2.
  5. Appel. Interner Forschungsbericht 1974, Fa. Thomae, Biberach/Riss. On file: Solvay Arzneimittel GmbH, Hannover, Deutschland.
  6. Aserkoff B, Benett JV. Effect of antibiotic therapy in acute salmonellosis on the faecal excretion of salmonellae. New Eng J Med 1969; 281:636-400.
  7. Ballongue J, Crociani J Grill JP. In vitro study of the effect of lactulose and lactitol on growth and metabolism of intestinal bacteria. Gut 1995; 37 (Sup-pi. 2):A48.
  8. Ballongue J, Schumann C, Quignon P. Effects of Lactulose and Lactitol on Colonic Microflora and Enzymatic Activity. Scand J Gastro-enterol 1997; 32 SuppI 222:41-44.
  9. Bass P, Dennis S. The laxative effects of lactulose in normal and constipated subjects. J Clin Gastroenterol 1981; 3:23-28.
  10. Baumjohann H, Schumann С, Rentz В. Rezidivierende Vaginal- und Darmmykosen - mil Lactulose zu behandein? notabene medici 1991; 21:273-5.
  11. Beckmann G, Ruffer A, Sonnenschein B. Lactulose und Darmmilieu. Konnen intestinale Hefen Lactulose verwerten? - Experimentelle Untersuchungen. Arztezeitschrift fur Naturheilver-fahren 1996:37:775-80.
  12. Bennet A, Eley KG. Intestinal pH and propulsion: an explanation of diarrhea in lactase deficiency and laxation by lactulose. J Pharm Pharmacol 1976; 28:192-195.
  13. Bernhardt H, Knoke M. Mycological aspects of gastrointestinal microflora. Scand J Gastroenterol 1997; 32 (SuppI. 222):102-6.
  14. Bianchi GP, De Mitri MS, Bugianesi E, Abbiati R, Fabbri A, Marchesini G. Lowering effects of a preparation containing fibres and lactulose on glucose and insulin levels in obesity. Ital J Gastroenterol 1994; 26:174-8.
  15. Bircher J, Haemmerii UP, Trabert E, Largiader F, Mocetti T. The mechanism of action of lactulose in portal-systemic encephalopathy. Nonionic diffusion of ammonia in the canine colon. Europ J ClinBiol Res 1971; 16:352.
  16. Bircher J, Mu Her J, Guggenheim P, Haemmerii UP. Treatment of chronic portal systemic encephalopathy with lactulose. Lancet 1966; 1:890-892.
  17. Bjarnason I, Macpherson A. Intestinal permeabiliy: Tests for diagnostic leaks or leaky diagnostic tests? Z Gastroenterol 1996; 34 (Suppl.4): 54-9.
  18. Boisson J. Trial with duphalac® (lactulose) for the withdrawal of irritant laxatives. Results of a double-blind, multi-centre clinical trial involving patients whose irritant laxatives were withdrawn overnight. LeConcours Medical 1991; 1-12.
  19. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotele-metry device. Gut 1974;15:99-1004.
  20. Brommage R, Juillerat MA, Jost R. Influence of casein phosphopeptides and lactulose on intestinal calcium absorption in adult female rats. Lait 1991:71: 173-80.
  21. Brommage R, Binacua C, Antille S, Carrie AL. Intestinal calcium absorption in rats is stimulated by dietary lactulose and other resistant sugars. J Nutr 1993; 123 (12): 2186-94.
  22. Bush RT. Lactulose: An ideal laxative for children. NZ Med J 1970; 71:364-365.
  23. Caruso G, Jelasi G, Cadeo GP. Terapia acidificante delle salmonellosi nell' infanzia [On the acidifying treatment of salmonelloses in infancy]. G Mal Infett Parassit 1981; 33:509-510.
  24. Castell PD, Moore EW. Ammonia absorption from the human colon: the role of nonionic diffusion. Clin Res 1968; 16:528-532.
  25. Champion MC, Gardiner D, Kilgour JA, Page J, Thompson WG, Oxbro C. Efficacy and cost effectiveness of lactulose (chronulac) in the treatment of constipation in elderly psychatric patients. A double-blind placebo-controlled crossover study. Am J Gastroenterol 1986; 81 (9):872.
  26. Clausen MR, Mortensen PB. Lactulose, Disaccharides and colonic flora. Clinical consequences. Drugs 1997; 53:930-42.
  27. Conn НО, Bircher J (Hrg.). Hepatic Encephalopathy: Management with lactulose and related carbohydrates. MediEd Press East Lansing, Michigan 1989.
  28. Conn НО, Floch MH. Effects of lactulose and Lactobacillus acidophilus on the fecal flora. Am J Clin Nutr 1970; 23:1588-94.
  29. Conn HO, Leevy CM, Vlahecevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalo-pathy: a doubleblind controlled trial. Gastroenterology 1977; 72:573-583.
  30. Conn НО, Lieberthal MM. The hepatic coma syndrome and lactulose. Williams & Wilkins, Baltimore 1979:368.
  31. Conn НО. The hepatic encephalopathies. In: Conn HO, Bircher J. (eds): Hepatic encephalopathies - syndromes and therapies. Medi-Ed Press, Bloomington 1994a:1-12.
  32. Conn НО. The theoretic therapy of hepatic encephalopathy. In: Conn HO, Bircher J. (eds): Hepatic encephalopathies - syndromes and therapies. Medi-Ed Press, Bloomington 1994b: 135-147.
  33. Conte D, Bardella MT, Bernardi M et al. Hypocholesterinemic effect of lactulose in man. Panminerva med 1977; 19 (1):1-4.
  34. Creytens G. Le Lactulose dans Ie traitement de la constipation chronique et I'abus des laxatifs. ars medici 1980; 35:737-57.
  35. Crowther AGO. Management of constipation in terminally ill patients. J Int Med Res 1978; 6:348-50.
  36. Cucchiara S, Coremans G, Staiano A, Corazziah E, Romaniello G, Di-Lorenzo C, Tamburrini 0, Auricchio S. Gastrointestinal transit time and anorectal manometry in children with fecal soiling. J Pediatric Gastroenterol & Nutrition 1984;3: 545-50.
  37. Demeulenaere L, Rottiers R, van Egmond J et al. Lactulose treatment of spontanous or induced paoxysmal hy-perammonemia and of chronic hyper-ammonemia in the cirrhotic patient. Problemes de Reanimation 1969; 5: 855-68.
  38. Demeulenaere L, Van Waes L, van Egmond J. Emergency treatment of acute portalsystemic encephalopathy (PSE) with lactulose enemas: -A control led study. (Abstract) Gastroenterology 1977:72:1174.
  39. Doffoel M. Etude du duphalac® (Lactulose) dans le traitement des patients presentant des hemorrhoides ou une fissure anale. Med Chir Dig 1992; 21: 165-8.
  40. Duffy LC, Riepenhoff-Talty M, Byers ТЕ et al. Modulation of rotavirus enteritis during breast feeding. Implications on alterations in the intestinal bacterial flora. Am J Dis Childr 1986; 140:1164-8.
  41. Duffy LC, Zielezny MA, Riepenhoff-Talty M et al. Effectiveness of Bifidobacterium bifidum in experimentally induced MRV infection: dietary implications in formulas for newborns. Endocr Regulations 1993: 27:223-9.
  42. Dunker-Schmidt С, Schumann С. Lactulose-Pulver - wirksam bei Candi-da-Mykosen des Darms? Arztliche Praxis 1998(inDruck).
  43. Egberts EH. Therapie der hepatischen Enzephalopathie. Leber Magen Darm 1987; 17:244-73.
  44. Elkington SG, Flock MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N EngI J Med 1969; 281:408-412.
  45. Engelhardt F, Schreier K. Lactulose in der Behandlung der Sauglings- und Kleinkinderobstipa-tion. Med Ernahr 1972; 13:124-125.
  46. Ewe К, Ueberschaer В, Press AG, Kurreck C, Klump M. Effect of lactose, lactulose and bisacodyl on gastroin-testinal transit studied by metal detector. Aliment Pharmacol Ther 1995; 9 (1):69-73.
  47. Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalo-pathy. J Parent Ent Nutr 1996; 20:159-64.
  48. Fiordaliso M, Kok N, Desager JP, Goethals F, Deboyer D, Roberfroid MB, Delzenne N. Dietary Oligofructose Lowers Triglycerides, Phospholipids and Cholesterol in Serum and Very Low Density Lipoproteins of Rats. Lipids 1995; 30:163-167.
  49. Fong IW. The rectal carriage of yeast in patients with vaginal candidiasis. Clin Invest Med 1994; 17:426-31.
  50. Franke N. Obstipation - mehr als eine Befindlichkeitsstorung. der niedergelasseneArzt 1991:40:18.
  51. Fulton JD. Infection limitation with lactulose therapy. J Clin Exp Gerontology 1988/89; 10(3&4):117-24.
  52. Gardiner KR, Erwin PJ, Anderson NH, McCaigue MD, Halliday Ml, Rowlands BJ. Lactulose as an antiendotoxin in experimental colitis. Br J Surg 1995; 82:469-72.
  53. Gattuso JM, Kamm MA. Review article: the management of constipation in adults. Aliment Pharmacol Ther 1993; 7:487-500.
  54. Geerke H. Untersuchungen zur Moglichkeit der Auflosung von Cholesteringallensteinen durch Lactulose oder Terpene in Kombination mit Gallensauren. Bonn: Universitat Bonn 1984, Dissertation.
  55. Genovese S, Riccardi G, Rivellese AA. Lactulose improves blood glucose response to an oral glucose test in noninsulin dependent diabetic patients. DNM 1993;5(4):295-297.
  56. Gibson GR, Roberfroid MB. Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J Nutr 1995; 125:1401-1412.
  57. Gleason W, Figueroa-Colon R, Robinson LH et al. A double-blind, parallelgroup, placebo-controlled study of lactulose in the treatment of encopresis in children with chronic constipation. Gastroenterol 1995; 108 (4; Suppl.):A606.
  58. Gottlieb SH, Schuster MM. Dermatoglyphic (fingerprints) evidence for a congenital syndrome of early onset constipation and abdominal pain. Gastroenterology 1986, 91:428-32.
  59. Greiser E, Molzahn M. Ratgeber Abfijhrmittel. Bremer Institut fur Sozial- und Praventionsforschung, Institut fur Nieren-und Hochdruck-forschung, Berlin, 1996.
  60. Grunewald Th, Schumann C, Huchzermeyer H. Determination of orocaecal transit time by hydrogen exhalation test - comparison of lactulose and lactitol. (In Vorbereitung 1998).
  61. Gschwantler M. Gebauer A, Vavrik J, et al. Acute and chronic complications after implantation of a transjugular intrahepatic portosystemic shunt - a prospective study in 53 patients. Z Gastroenterol 1997; 35:999-1005.
  62. Hansson HB, Barkenius G, Cronberg S, Juhlin I. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis. Scand J Infect Dis 1981; 13:191-3.
  63. Harris AC, Jackson JM. Lactulose in vincristine-induced constipation. Med J Austr 1977:2:573-574.
  64. Heaton KW, Radvan J, Cripps H, Mountford RA, FEM Braddon, Hughes АО. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33:818-24.
  65. Heckers H. Obstipation in der Schwangerschaft - welche Therapie? Gynakologe 1987;20:171-175.
  66. Hedger RW, Ing TS, Wang F, Kovithavongs T. Lactulose therapy in chronic renal failure. J Lab Clin Med 1971; 78:1015.
  67. Held С, Briedigkeit H, Hagemann I. Resorption und renale Effekte von Neomycin bei experimenteller Leberzirrhose. Z klin Med 1991; 46:1009-10.
  68. Held С, Briedigkeit H. Hepatische Encephalopathie: Langzeittherapie mit Neomycin problematisch. Z a'rztl Fortbild 1992:86:367-70.
  69. Hoffmann К, Mossel DAA, Korus W, van de Kamer J. Untersuchun-gen liber die Wirkungsweise der Lactulose. Klin Wochenschr 1964; 42:126-130.
  70. Hoffmann К. Behandlung von gesunden Salmonellen-Ausschei-dern mit Lactulose. Dtsch Med Wochenschr 1975; 100:1429-1431.
  71. Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11:165-70.
  72. Huchzermeyer H, Schumann C. Lactulose - a multifaceted substance. Z Gastroenterol 1997; 35: 945-55.
  73. Igarashi C, Ezawa I. Effects of whey calcium and Lactulose on the strength of bone in ovariectomized osteoporosis model rats. Pharma-cometrics (Jpn) 1991;42(3):245-54.
  74. Imler M, Kurtz D, Bockel R, Stahl J. Etude comparative du traitement de I 'encephalopathie portocave par Ie lactulose, les bacilles lactiques et les anti-biotiques. Therapeutique 1971; 47:237-248.
  75. Ingelfinger F. Editorial comments; in Beeson PB et al. (eds.): Year book of medicine. Chicago, Year Book Medical, 1964-1965, pp 591-592.
  76. Isolauri E, Juntunen M, Rautanen Т, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhoea in children. Pediatrics 1991;88:90-7.
  77. Josimovic IB. Die Verhutung des Dickdarmkrebses durch Lactulose. Krebsgeschehen 1979; 6:175-8.
  78. Keeling WF, Harris A, Martin BJ. Orocecal transit during mild exercise in women. J AppI Physiol 1990; 68:1350-3.
  79. Kist M. Salmonellen-Enteritis. Lactulose beschleunigt die PathogeneElimination. Selecta 1980; 46:4050-1.
  80. Kitler ME, Luginbiihl M, Lang 0, Wuhl F, Wyss A, Lebek G. Lactitol and Lactulose. An in vivo and in vitro compari-son of their effect on the human intesti-nai flora. Drug Invest 1992; 4(1 ):73-82.
  81. Knothe H, Knapp G, Meyer M et al. Zur Therapie bei Salmonellen-Enteriti-den unter Berucksichtigung von Lactulose. Infektion 1980; 8:294-298.
  82. Kolinger M, Kulimann F, Holstege A, Scholmerich J. Prophylaxe und Therapie von Komplikationen der Leberzirrhose: Ascites, Enzephalo-pathie und Malnutrition. Med Klinik 1996; 91:89-102.
  83. Kruger M, Schumann C. Lactulose treatment of constipation in the elderly. (Publikation in Vorbereitung. Data on file, Solvay Arzneimittel 1994, Report numberH.105.904.G).
  84. Kuznetsov VF, Yushchuk ND, Yurko LP, Nabokova NY. Intestinal dysbacte-riosis in patients with yersiniosis and pseudotuberculosis and ist correction with biological preparations (RUSS.).TerArkh 1994; 66:17-8.
  85. Lachgar M, Morer I. Etude de I'efficacite et de la tolerance du lactulose dans la constipation chez la femme enceinte. Rev Fr Gynecol Obstet 1985; 80:663-665.
  86. Laker MF, Menzies IS. Increase in human intestinal permeability following ingestion of hypertonic solutions. J Physiol 1977; 265:881-894.
  87. Lembcke B. Current role of breath tests in gastroenterology. Z Gastro-enterol 1996;34(Suppl.4):46-53.
  88. Lentzen H, Kulle EU, Daschner F. Vergleichende Untersuchung der Serumspiegel und Urinausscheidung nach oraler Gabe von Paromomycin und Neomycin, Drug Res 1981; 31:1967-71.
  89. Leung AKC, Chan PYH, Cho HYH. Constipation in children. Am Farn Physician 1996:54:611-18.
  90. Levine MM, Hornick RB. Lactulose therapy in shigella carrier state and acute dysentry. Antimicrob Agents Chemother, 1975; 8(5):581-4.
  91. Liehr H, Englisch G, Rasenack U. Lactulose - a drug with antiendotoxin effect. Hepato-Gastroenterology 1980; 27:356-60.
  92. Liem KS. Biochemical report on the absorption of lactulose. Data on file, Solvay Arzneimittel 1966.
  93. London NJM; Bramley PD; Windle R. Effect of four days of preoperative lactulose on posthaemorrhoidectomy pain: Results of placebo controlled trial. Br Med J1987;295(6594):363-4.
  94. Low-Beer TS, Pomare EW. Can colo-nic bacterial metabolites predispose to cholesterol gallstones? Br Med J 1975; 1:438-40.
  95. Lubcke P, Freitag V, Sziegoleit M. Aktueller Stand der Therapie von Salrnonelleninfektionen. Therapiewoche 1976; 26:5394-5401.
  96. MacGillivray PC, Finlay HVL and Binns ТВ. Use of lactulose to create a preponderance of lactobacilli in the intestine of bottlefed infants. Scottish MedJ 1959; 4:182-189.
  97. Mack DJ, Smart L, Girdwood A, Scott PJW, Fulton JD, Erwin L. Infection prophylaxis with Lactulose. Age & Ageing 1993;22(Suppl.2):8(Nr. 18).
  98. Magan JLA, Soto CR. Lactulose (Duphalac®) in postpartum constipation. Pharmatherapeutica 1977: 1:430-433.
  99. Makinen KK, Rekola M. Comparison between sucrose and lactulose in a suspended salivary System. J Dent Res 1975:54:1244.
  100. Mann NS, Borkar BB, Narenderan KP et al. Effect of lactulose, neomycin, and antacid on colonic pH recorded with an implanted electrode. Am J Gastroenterol 1979:72:141-5.
  101. Marcus SN, Heaton KW. Deoxycholic acid and the pathogenesis of gallstones. Gut 1988; 29:522-33.
  102. Mason VC, Palmer R. The influence of bacterial activity in the alimentary canal of rats on faecal nitrogen excretion. Acta Agric Scand 1973:23:141-50.
  103. Matsuda Y, Uematsu Y, Shibamoto T, Koyama S. Evaluation of the effect of lactulose in a rabit model for acute renal failure. Medicin and Pharmacy (Jpn.) 1992;27(1):49-54.
  104. Matsutaka H, AikawaT, Yamamoto H, Ischikawa E. Gluconeogenesis and ami-noacid metabolism. III. Uptake of gluta-mine and Output of alanine and ammonia by non-hepatic splanchnic of fasted rats and their metabolic significance. J Biochem, Tokyo 1973: 74:1019-29.
  105. Mayerhofer F, Petuely F. Untersuchungen zur Regulation der Darmtragheit des Erwachsenen mit Hilfe der Lactulose (Bifidus-Faktor). Wien Klin Wochenschr 1959; 71:865-869.
  106. McCutcheon J, Fulton JD. Lowered prevalance of infection with lactulose therapy in patients in longterm hospital care. J Hosp Inf 1989; 13:81-6.
  107. McNamara DJ, Samuel P. Intestinal bacterial 7-a-Dehydroxylase activity: a regulator of plasmacholesterol in man? Arteriosclerosis 1981; 1:73.
  108. MenziesIS, Pounder R, HeyerS,etal. Abnormal intestinal permeability to sugars in villous atrophy. Lancet 1979; 2:1107-1109.
  109. Menzies IS. Absorption of intact oligosaccharide in health and disease. Biochem Soc Trans 1974; 2:1042-6.
  110. Miles MR, Olsen L, Rogers A. Recurrent vaginal candidiasis. Importance of an intestinal reservoir. J Am Med Assoc 1977; 238:1836-7.
  111. Miura M, Nomoto Y, Sakai H. Short term effect of lactulose in patients with chronic renal failure. Tokai J Exp Clin Med. 1989; 14(1):29-34.
  112. M, Kazumasa A, Tojo S. Lactulose therapy for chronic renal failure. JapJ Nephrol 1984; 8:1091-8.
  113. Montgomery E, Hudson CS. Transformation of lactose to a new disacchari-de, lactoketose. Science 1929; 69:556-557.
  114. Morgan MY. The treatment of chronic hepatic encephalopathy. Hepato-Gastroenterol 1991; 38:377-87.
  115. Mortenson PB, Holtug К, Bonnen H, Clausen MR. The degradation of amino acids, proteins, and blood to short chain fatty acids in colon is prevented by lactulose. Gastro-enterology 1990; 98:353-60.
  116. Moynihan PJ, Russell RRB. Implications of prebiotics for dental health. In: Hartemink (ed). Non-digestible oligosaccarides: healthy food for the colon? Graduate School VLAG, Wageningen, the Nethe-rlands, 1997:132.
  117. Muller M, Jaquenoud-Sirot E. Behand-lung der chronischen Obstipation bei Kindern mit Lactulose. Ars Medici 1994:84:568-74.
  118. Muller M, Jaquenoud E. Behandlung der Obstipation bei Schwangeren. Schw MedWschr 1995; 125:1689-93.
  119. Nagengast FM, Hectors MPC, Buys WAM, Van Tongeren JHM. Inhibition of secondary bile acid formation in the large intestine by lactulose in healthy subjects of two different age groups. Europ J Clin Invest 1988; 18:56-61.
  120. Nolle W, Ramadori G. Therapie der hepatischen Enzephalopathien. Dtsch medWschr1996; 121:699-701.
  121. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomy-cin and lactulose in 173 patients with hepatic encephalopathy. A randomized clinical study. Dig DisSci 1981; 26:498-506.
  122. Orlandi F, Brunelli E, Benedetti A, Macarri G. Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy. In: Conn HO, BircherJ. (eds): Hepatic encephalopathies - syndromes and therapies. Medi-Ed Press, Bloomington 1994: 209-17.
  123. Ozgelik MF, Pekmezci S, Altinii E, Eroglu C, Goksel S, Goksoy E. Lactulose to prevent translocation in biliary obstruction. Dig Surg 1997: 14:267-71.
  124. Orskov ER, Fraer C, Mason VC, Mann SO. Influence of starch digestion in the large intestine of sheep on caecal fermentation, caecal microflora and faecal nitrogen excretion. Br J Nutr 1970; 24:671-82.
  125. Paigen К, Williams В. Catabolite repression and other control mechanisms in carbohydrate utilization. Adv MicrobiolPhysiol 1970:4:251-324.
  126. Pain JA, Bailey ME. Experimental and clinical study of lactulose in obstructive jaundice. Br J Surg 1986; 73: 775-8.
  127. Pain JA, Cahill CJ, Gilbert JM, Johnson CD, Trapnell JE, Bailey ME. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a multicentre study of bile salts and lactulose. Br J Surg 1991 ;78: 467-9.
  128. Palmie РЕ. Zur Behandlung der Obstipation im Kindes- und Jugendalter. Therapiewoche 1980; 30: 4045-4049.
  129. Pearson ADJ, Eastham EJ, Laker MF, et al. Intestinal permeability in children with Crohn's disease and coeliac disease. BrMedJ 1982:285:20-21.
  130. Perkin JM. Constipation in childhood: a controlled comparison between lactulose and standardized senna. Curr Med ResOpin 1977; 4:540-543.
  131. Petuely F. Der Bifidusfaktor. Dt Med Wschr 1957; 82:1957-60.
  132. Petuely F. Uber den Bifidusfaktor Lactulose. Bifidobacteria Microflora 1986; 5:3-11.
  133. Pirotte J, Guffens JM, Devos J. Comparative study of basal arterial ammonaemia and of orally induced hyperammonaemia in chronic portal-systemic encephalopathy treated with neomycin, lactulose and association of neomycin and lactulose. Digestion 1974; 10:435-444.
  134. Plauth M, Egberts EH. Was ist gesichert in der Therapie der hepatischen Enze-phalopathie? Internist 1993:34:35-42.
  135. Plauth M, Raible A, Graser ТА, Noldeke IL, Furst P, Dolle W, Hartmann F. Lactulose or paromomycin do not affect ammonia generation in the isolated perfused rat small intestine. Z Gastroenterol 1994; 32:141-5.
  136. Poralla Т. Portosystemische Enzephal-opathie. In: Hepatologie in Klinik und Praxis. Grundlagen, Diagnostik und Therapie. Hrg.: K-H Meyer zum Buschenfelde.W Arnold, THHutten-roth. Georg Thiei-ne Verlag Stuttgart, New York 1989; 313-327.
  137. Porter N. The use of lactulose in posthaemorrhoidectomy patients. Br J Clin Pract 1975; 29:235-6.
  138. Pye G, Evans DF, Ledingham S, Hardcastle JD. Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma. Gut 1990;31:1355-7.
  139. Quarto di Palo F, Buccianti G, Civardi F. Use of lactulose in the treatment of chronic renal failure. Minerva Med 1978; 69 (7):455-60.
  140. Ratnaike RN, Hicks EP, Hislop IG. The rectal administration of lactulose. Aust NZJmed 1975:5:137-40.
  141. Rendtorf RC, Kashgarian M. Stool patterns of healthy adult males. Dis Colon Rectum 1967; 10:222-228.
  142. Roberfroid MB. Dietary Fiber, Inulin, and Oligofructose: a Review Comparing their Physiological Effects. Critical Reviews in Food Science and Nutrition 1993; 33:103-148.
  143. Robert-Koch-lnstitut und Bundesinstitut fur gesundheitlichen Verbraucherschutz und Veterinarmedizin (Hrg.). Salmonellose - Erkennung, Bekampfung, Verhutung. Merkblatt fur Arzte. Bundesgesundheitsbl. 1997; (1):36-8.
  144. Roncucci L, Di Donato P, Carati L, Ferrari A, Perini M, Bertoni G, Bedogni G, Paris B, Svanoni F, Girola M, Ponz de Leon M. Antioxidant vitamins or Lactulose for the prevention of the recurrence of colorectal adenomas. Dis Colon Rectum 1993; 36:227-34.
  145. Rotstein OD, Kay RM, Wayman M, Strasberg SM. Prevention of cholesterol gallstones by lignin and lactulose in the hamster. Gastro-enterology 1981 a; 81:1098-1103.
  146. Rotstein OD, Kay RM, Wayman M, Strasberg SM. Hypocholes-terolemic effect of dietary fiber and lactulose. Arteriosclerosis 1981b; 1:73-74.
  147. Rowland IR, Bearne CA, Fischer R, Pool-Zobel BL. The effect of lactulose on DNA damage induced by DMH in the colon of human flora-associated rats. Nutr Cancer 1996; 26:37-47.
  148. Ryan D, Wilson A, Muir TS, Judge TG. The reduction of faecal incontinence by the use of "Duphalac®" in geriatric patients. Curr Med Res Opin 1974:2:329-333.
  149. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoes and shedding of rotavirus. Lancet 1994; 344 (8929):1046-9.
  150. Sander-Treske R, Czermak L. Lactulose bei Salmonellenenteritis - eine Alternative zur antibiotischen Chemotherapie. Therapiewoche 1980; 31:1213-17.
  151. Sanders JF. Lactulose syrup assessed in a double-blind study of elderly constipated patients. J Am Geriat Soc 1978; 26:236-239.
  152. Sandier RS, Jordan MC, Shelton BJ. Demographic and dietary determinations of constipation in the US population. AM J Publ Health 1990: 80 (2): 185-9.
  153. Scevola D, Zambelli A, Concia E, Perversi L, Candiam C. Nona-bsorbable disaccharides plus neomycin in hepatic encephalopathy: Do they enhance each other? La Clinica Terapeutica1989;129:105-11.
  154. Schalm SW, Van der Mey T. Hyperammonemic coma after hepatectomy in germfree rats. Gastroenterology 1979; 77:231-4.
  155. Schettler G (Hrsg). Innere Medizin. Ein kurzgefaBtes Lehrbuch. Georg Thieme Verlag Stuttgart, New York, 1987. Bd. II, S.421.
  156. Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dolle W. Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 1981;26(7):622-630.
  157. Schomerus H, Schreiegg J. Prevalence of latent portasystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice. Z Gastroenterol 1993; 31:231-4.
  158. Schumann С. Herausforderung Lactulose. I. Zur cholesterinsenkenden Wirkung von Lactulose. Z arztl Fortbild 1992; 86:901-904.
  159. Schumann С. Herausforderung Lactulose. II. Bedeutung der Regulation des enterischen Gallen-saurekreislaufs durch pH-Wert-Senkung fur die Lithogenese. Z arztl Fortbild 1992; 86:905-908.
  160. Schumann С. Darm-Mykosen. Behandiung durch Regulation des Okosy-stems Darm. Die РТА in der Apotheke 1996:25:168-71.
  161. Schumann С. Die immunologischen Effekte der Lactulose. notabene medici 1997; 27:188-90.
  162. Soeters PB, Van Leeuwen РАМ. Ammoniak und Glutaminstoffwech-sel des Darms. EinfluB von Lactulose und Neo-mycin. Infusionsther. 1986; 13:186-90.
  163. Stephen AM, Cummings JH. Mechanism of action of dietary fiber in the human colon. Nature 1980; 284:283-4.
  164. Terada А, Нага H, Kataoka M, Mitsuoka T. Effect of lactulose on the composition and metabolic activity of the human faecal flora. Microbial Ecology in Health and Disease 1992; 5:43-50.
  165. Thornton JR, Heaton KW. Do colonic bacteria contribute to cholesterol gallstone formation? Effects of lactulose on bile. Br Med J 1981; 282(6269): 1018-20.
  166. Tomoda T, Nakano Y, Kageyama T. Intestinal Candida overgrowth and Candida infection in patients with leukemia: effect of Bifidobacterium administration. Bifidobacteria Microflora 1988; 7:71-4.
  167. Towers AL, Burgio KL Locher JL, Merkel IS, Safaeian M, Wald A. Constipation in the elderly: Influence of dietary, psychological, and physiological factors. J Am Geriatr Soc 1994; 42:701-6.
  168. Tramonte SM, Brand MB, Mulrow CD, Amato MG, O'Keefe ME, Ramirez G. The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med 1997; 12:15-24.
  169. Van Berge Henegouwen GP, van der Werf SDJ, Ruben AT. Effect of lactulose on biliary lipid composition. J Hepatology 1986; 3:328-32.
  170. Van Berge Henegouwen GP, van der Werf SDJ, Ruben AT. Effect of long term lactulose ingestion on secondary bile salt metabolism in man: potential protective effect of lactulose in colonic carcinogenesis. Gut 1987; 28:675-680.
  171. van Leeuwen РАМ. Ammonia generation in the gut and the influence of lactulose and neomycin. Dissertation; Universitat Limburg, Maastricht, Niederlande 1985.
  172. van Leeuwen РАМ, Hong RW, Rounds JD, Wilmore DW, Wesdorp RIC. Hepatic failure and coma following liver resection is reversed by manipulation of gut contents: the role of endotoxin. Surgery 1991; 110:169-75.
  173. Velio P, Bassotti G. Chronic idiopathic constipation: Pathophysiology and treatment. J Clin Gastroenterol 1996; 22:190-6.
  174. Vince AJ, Zeegen R, Drinkwater JE, O'Grady F, Dawson AM. The effect of lactulose on the fecal flora of patients with hepatic encephalopathy. J Med Microbiol 1974; 7:163-8.
  175. Vince A, Killingley M, Wrong OM. Effect of lactulose on ammonia production in a fecal incubation system. Gastroenterology 1978: 74: 544,549.
  176. Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: The effects of lactose, lactulose and glucose. J Med Microbiol 1980; 13:177-91.
  177. Visco G, Costa M, Leoni GC, et al. Terapia acidificanti nelle gastroenteriti dell' adulto da Salmonelle "minori" [Acidifying therapy in adults affected by "minor" Salmonella gastroenteritis]. G Mal Infett Parassit 1981; 33:514-517.
  178. Vonk RJ (ed.): Manipulation of colonic flora as ecosystem and metabolic organ: consequences for the organism. (Proceedings of the symposium: Lactulose - 30 years after, June 1996, Witten, Germany). Scand J Gastroenterol 1997; 32(Suppl222):1-114.
  179. Von Klinggraff C. Zur Therapie der Obstipation bei Kleinkindern, Kindern und Jugendlichen. Kinderarzt 1981; 6:1-3.
  180. Vugt H van, Gool J van, Thomas LLM. Galactosamine hepatitis, endotoximia, and lactulose. Hepatology 1981; 3(2):236-40.
  181. Weber FL Jr. Effect of lactulose on urea and nitrogen metabolism in cirrhotic patients. Gastroenterology 1979; 77:18-23.
  182. Weber FL. Hepatic encephalopathy. Gastroenterology 1984; 4:197-237.
  183. Weber FL. Combination therapy with lactulose and antibiotics. In: Conn Ho Bircher J. Hepatic Encephalopathy - Management with lactulose and related carbohydrates. Medi-Ed Press, East Lansing, Michigan, 1989, S. 207-217.
  184. Weber FL Jr. Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. Dig Dis 1996; 14(Suppl. 1):53-63.
  185. Weber FL Jr. Effects of lactulose on nitrogen metabolism. Scand J Gastroenterol 1997; 32 (Suppl. 222):83-87.
  186. Weber FL, Veach G. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979; 77:235-40.
  187. Weber FL, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982; 82:213-217.
  188. Werner GT. Therapeutische Probleme bei Salmonellen-Dauerausscheidern. Therapie der Gegenwart 1979; 118:235-242.
  189. Wesselius de Casparis A, Braadbaart S, Van den Bergh-Bohlken GE, Mimica M. Treatment of chronic constipation with lactulose syrup: results of a double blind study. Gut 1968; 9:84-86.
  190. Westphal G. Ernahrungsphysiologie und Toxikologie von Maillard-Reaktionsprodukten. 1. Reaktionsmechanismen in vitro und in vivo. Ernahr-Umschau 1992; 39:450-2.
  191. Wettstein M, Haussinger D. Hepatische Enzephalopathie, Diagnostik und Therapie. Med Klinik 1996: 91:447-8.
  192. Wheeler PG, Menzies IS, Creamer B. Effect of hyperosmolar stimuli and coeliac disease on the permeability of the human gastrointestinal tract. Clin Sci Mol Med 1978; 54:495-501.
  193. Whitehead WE, Chaussade S, Corazziari E, Kumar D. Report of a international workshop on management of constipation. Gastroenterol Int 1991; 3:99-113.
  194. Wilson A, Ryan D, Muir TS. Geriatric faecal incontinence - a drug trial conducted by nurses. Nurs Mirror 1975; 140: 50-52,
  195. WindmullerHG, SpaethAE. Uptake and metabolism of plasma glutamine by the small intestine. J biol Chem 1974; 249:5070-79.
  196. Wizemann V, Spring M, Rink W, Schutterle G. Lactulose in chronic renal failure: Action on aromatic amines and phosphate. Kidney Int 1983; suppLS.341.
  197. Zeegen R, Drinkwater JE, Fenton JCB, Vince A, Dawson AM. Some observations on the effects of treatment with lactulose with chronic hepatic encephalopathy. Quant J Med 1970; 39:245-263.

Solvay Pharma Реклама: SOLVAY Бесплатный интернет-доступ к сайту
Баннерная сеть Солвей-Фарма.ру

Последнее обновление  31.12.2008 г.